Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
Executive Summary
The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003
You may also be interested in...
EPO Ceasefire? Amgen Aranesp Price To Remain Stable Unless J&J Acts First
Amgen does not intend to continue implementing Aranesp price discounts unless J&J moves first, Amgen Exec VP-Global Commercial Operations George Morrow said during an earnings call April 22
EPO Ceasefire? Amgen Aranesp Price To Remain Stable Unless J&J Acts First
Amgen does not intend to continue implementing Aranesp price discounts unless J&J moves first, Amgen Exec VP-Global Commercial Operations George Morrow said during an earnings call April 22
“Functional Equivalence” For 2004: Aranesp OPPS Payment Is 78% Of AWP
Medicare will reimburse Amgen's Aranesp at about 78% of AWP under a revised Hospital Outpatient Prospective Payment System rule